Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Wang, Lei ^a   Feng, Jianfang ^b   Chen, Xiaonan ^c   Guo, Wei ^c   Du, Yuwen ^c   Wang, Yuanyuan ^c   Zang, Wenqiao ^c   Zhang, Shijie ^a   Zhao, Guoqiang ^c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

5 fluorouracil; Chemosensitizer; Esophageal carcinoma; Myricetin

Indexed keywords

CASPASE 3; CHOLECYSTOKININ OCTAPEPTIDE; CYCLIN D; FLUOROURACIL; MYRICETIN; PROTEIN BCL 2; PROTEIN P53; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CHEMOSENSITIZATION; COLONY FORMATION; CONTROLLED STUDY; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84905975473     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0071-2     Document Type: Article

References (40)

1. Szumiło J. Epidemiology and risk factors of the esophageal squamous cell carcinoma. Pol Merkur Lekarski 2009, 26:82-85. 19391515.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
3. Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs 2009, 14:329-339. 10.1517/14728210902976842, 19453287.
4. Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, Li JM, Kong GQ, Qi H, Cui J, Zhang LQ, Yang JZ, Li JL, Li XC, Ren JL, Liu ZC, Gao WJ, Yuan L, Wei W, Zhang YR, Wang WP, Sheyhidin I, Li F, Chen BP, Ren SW, Liu B, Li D, Ku JW, Fan ZM, Zhou SL. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet 2010, 42:759-763. 10.1038/ng.648, 20729853.
5. Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010, 16:3793-3803. 10.3748/wjg.v16.i30.3793, 20698042.
6. Neuner G, Patel A, Suntharalingam M. Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res 2009, 3:57-65. 19461907.
7. Shah MA, Kelsen DP. Combined modality therapy of esophageal cancer: changes in the standard of care?. Ann Surg Oncol 2004, 11:641-643. 10.1245/ASO.2004.04.907, 15197008.
8. Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg 2013, 61:330-335. 10.1007/s11748-013-0246-0, 23568356.
9. Nabeya Y, Ochiai T. Chemotherapy for esophageal cancer. Gan To Kagaku Ryoho 2003, 30:1873-1880. 14650953.
10. Wang J, Yang ZR, Dong WG, Zhang JX, Guo XF, Song J, Qiu S. Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma. World J Gastroenterol 2013, 19:8292-8300. 10.3748/wjg.v19.i45.8292, 24363520.
11. Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Oncol Rep 2012, 27:1639-1645. 22293713.
12. Tian F, Zhang C, Tian W, Jiang Y, Zhang X. Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice. Oncol Rep 2012, 28:232-240. 22552693.
13. Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, Rao H, Wang Z, Greenson JK, Giordano TJ, Orringer MB, Rehemtulla A, Bhojani MS, Beer DG, Chang AC. Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol 2010, 3:99-108. 10.1593/tlo.09235, 20360934.
14. Gao Y, Hu N, Han XY, Ding T, Giffen C, Goldstein AM, Taylor PR. Risk factors for esophageal and gastric cancers in Shanxi Province, China: a case-control study. Cancer Epidemiol 2011, 35:e91-e99. 10.1016/j.canep.2011.06.006, 21846596.
15. Oze I, Matsuo K, Hosono S, Ito H, Kawase T, Watanabe M, Suzuki T, Hatooka S, Yatabe Y, Hasegawa Y, Shinoda M, Tajima K, Tanaka H. Comparison between self-reported facial flushing after alcohol consumption and ALDH2 Glu504Lys polymorphism for risk of upper aerodigestive tract cancer in a Japanese population. Cancer Sci 2010, 101:1875-1880. 10.1111/j.1349-7006.2010.01599.x, 20518787.
16. Veugelers PJ, Porter GA, Guernsey DL, Casson AG. Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006, 19:321-328. 10.1111/j.1442-2050.2006.00602.x, 16984526.
17. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H, West AB, Rotterdam H, Blot WJ, Fraumeni JF. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:1055-1062. 11588131.
18. Ong KC, Khoo HE. Biological effects of myricetin. Gen Pharmacol 1997, 29:121-126. 10.1016/S0306-3623(96)00421-1, 9251891.
19. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002, 22:19-34. 10.1146/annurev.nutr.22.111401.144957, 12055336.
20. Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev 2012, 31:323-351. 10.1007/s10555-012-9347-y, 22314287.
21. Sun F, Zheng XY, Ye J, Wu TT, Wang JL, Chen W. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 2012, 64:599-606. 10.1080/01635581.2012.665564, 22482362.
22. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005, 115:1492-1502. 10.1172/JCI23002, 15902309.
23. O'Neill OM, Johnston BT, Coleman HG. Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 2013, 19:5806-5812. 10.3748/wjg.v19.i35.5806, 24124325.
24. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013, 19:5598-5606. 24039351.
25. Anderson SE, Minsky BD, Bains M, Kelsen DP, Ilson DH. Combined modality therapy in esophageal cancer: the Memorial experience. Semin Surg Oncol 2003, 21:228-232. 10.1002/ssu.10041, 14648780.
26. Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fujii Y. Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography. Eur J Cancer 2000, 36:2164-2170. 10.1016/S0959-8049(00)00297-5, 11044656.
27. Pera M, Gallego R, Montagut C, Marti´n-Richard M, Iglesias M, Conill C, Reig A, Balague´ C, Pe´triz L, Momblan D, Bellmunt J, Maurel J. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol 2012, 23:664-670. 10.1093/annonc/mdr291, 21652581.
28. Chen R, Hollborn M, Grosche A, Reichenbach A, Wiedemann P, Bringmann A, Kohen L. Effects of the vegetable polyphenols epigallocatechin-3-gallate, luteolin, apigenin, myricetin, quercetin, and cyanidin in primary cultures of human retinal pigment epithelial cells. Mol Vis 2014, 20:242-258. 24623967.
29. Zhang S, Wang L, Liu H, Zhao G, Ming L. Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells. Diagn Pathol 2014, 9:68. 10.1186/1746-1596-9-68, 24650056.
30. Massague´ J. G1 cell-cycle control and cancer. Nature 2004, 432:298-306. 10.1038/nature03094, 15549091.
31. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005, 23:9408-9421. 10.1200/JCO.2005.01.5594, 16361640.
32. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166. 10.1038/nrc2602, 19238148.
33. Konstantinidou AE, Korkolopoulou P, Patsouris E. Apoptotic markers for tumor recurrence: a minireview. Apoptosis 2002, 7:461-470. 10.1023/A:1020091226673, 12207179.
34. Yano M, Inoue M, Shiozaki H. Preoperative concurrent chemotherapy and radiation therapy followed by surgery for esophageal cancer. Ann Thorac Cardiovasc Surg 2002, 8:123-130. 12472392.
35. Ferreira VA, Czeczko NG, Ribas-Filho JM, Malafaia O, Ribas CA, Gomes CS, Cunha RM, Cuenca RM. CD-34 and CASPASE-3 biomarkers expression in esophageal epidermoid carcinoma. Rev Col Bras Cir 2009, 36:35-41. 10.1590/S0100-69912009000100008, 20076866.
36. Ikeguchi M, Yamaguchi K, Kaibara N. Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol 2003, 24:40-45. 10.1159/000070659, 12743425.
37. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589. 10.1038/sj.onc.1207113, 14634620.
38. Itaya M, Yoshimoto J, Kojima K, Kawasaki S. Immunohistochemistry of p53, Bcl-2, and Ki-67 as predictors of chemosensitivity. Methods Mol Med 2005, 110:213-227. 15901938.
39. Hsia JY, Chen CY, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY, Chen JT. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma 2001, 48:483-488. 11949842.
40. Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001, 14:165-171. 11774736.